Feed MRNA
MR

Moderna MRNA · NASDAQ

$222.76 +4.01% (+$8.59)

Market cap
$88.9B
Enterprise value
$88.5B
P/E
-
Forward P/E
-
PEG
-
P/S
39.9x
P/FCF
-
EV/EBITDA
-
ROIC
-40.0%
Gross margin
-12.6%
Net margin
-141.4%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.90
Free float
93.2%

About the company

Moderna (MRNA) is a biopharmaceutical company specializing in the development of innovative drugs and vaccines. Their primary focus is on mRNA technology, which enables the creation of therapeutic and preventive products with high efficacy and safety. Moderna gained significant attention for its development of a COVID-19 vaccine, which has been approved and successfully deployed worldwide. Moderna stock is suitable for investors interested in the biotechnology sector and seeking opportunities in the field of therapeutic innovations and vaccines. Add Moderna stock to your watchlist on Bulios and be the first to receive updates on new developments, medical breakthroughs, and vaccines from this prominent company.

Sector

Healthcare

Industry

Biotechnology

CEO

Stéphane Bancel

Employees

4,700

Headquarters

Cambridge

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: It beat profit estimates 8 times in the last 8 quarters.
  • What to watch: Revenue fell by 53% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $1.72B against $1.29B.
  • What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy